尿激酶静脉溶栓治疗急性脑梗死的临床效果  

Clinical Effect of Intravenous Urokinase Thrombolytic Therapy on Acute Cerebral Infarction

作　　者：刘永忠 LIU Yongzhong(Department of neurology,Zhangping Hospital,Longyan,Fujian 364400,China)

机构地区：[1]漳平市医院神经内科,福建龙岩364400

出　　处：《中国医药指南》2025年第11期91-94,共4页Guide of China Medicine

摘　　要：目的分析治疗急性脑梗死时使用尿激酶静脉溶栓治疗的效果。方法选取2021年1月至2023年12月漳平市医院收治的急性脑梗死患者183例,以随机信封法分组,对照组91例患者为常规治疗联合阿替普酶溶栓治疗;观察组92例患者在此基础上增用尿激酶静脉溶栓治疗,对比两组治疗有效率、血浆黏度(PV)、纤维蛋白原(FIB)、C反应蛋白(CRP)、美国国立卫生院卒中量表评分(NIHSS)、简易生活质量量表评分(SF-36)、不良反应发生率。结果观察组治疗总有效率高于对照组(P<0.05)。治疗后观察组PV、FIB、CRP水平下降幅度均大于对照组(P<0.05)。治疗后,观察组NIHSS评分低于对照组(P<0.05)。观察组治疗后SF-36评分高于对照组(P<0.05)。两组不良反应发生率对比,差异无统计学意义(P>0.05)。结论尿激酶静脉溶栓治疗急性脑梗死时可显著提升临床疗效,改善受损的神经功能及相关指标水平,改善患者生活质量,且用药安全性较好。通过深入分析急性脑梗死的发病机制,不仅加深了对该疾病的认识,还成功开发出一系列针对特定病理环节的创新疗法。Objective Analysis of the effect of intravenous thrombolysis with urokinase in the treatment of acute cerebral infarction death Methods A total of 183 patients with acute cerebral infarction admitted to Zhangping City Hospital from January 2021 to December 2023 were selected and divided into groups using the random envelope method.The control group consisted of 91 patients who received conventional treatment combined with alteplase thrombolytic therapy.The observation group included 92 patients who,in addition to the conventional treatment and alteplase thrombolytic therapy,also received urokinase intravenous thrombolysis.The study compared the effective rate of treatment,plasma viscosity(PV),fibrinogen(FIB),C-reactive protein(CRP),National Institutes of Health Stroke Scale score(NIHSS),Short Form Health Survey score(SF-36),and the incidence of adverse reactions between the two groups.Results The total effective rate of treatment in the observation group was higher than that in the control group(P<0.05).After treatment,the decreases in PV,FIB,and CRP levels in the observation group were all greater than those in the control group(P<0.05).After treatment,the NIHSS score in the observation group was lower than that in the control group(P<0.05).The SF-36 score in the observation group was higher than that in the control group after treatment(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions Intravenous thrombolysis of urokinase can significantly improve the clinical efficacy,improve the level of impaired neurological function and related indicators,improve the quality of life of patients,and have good drug safety in the treatment of acute cerebral infarction.The in-depth analysis of the pathogenesis of acute cerebral infarction not only deepens our understanding of the disease,but also successfully develops a series of innovative methods for treating specific pathological connections.

关 键 词：急性脑梗死 尿激酶 静脉溶栓治疗 神经功能 生活质量 

分 类 号：R743.3[医药卫生—神经病学与精神病学]